Diagnostyka S.A. (WSE:DIA)
Poland · Delayed Price · Currency is PLN | Market Cap | 5.51B -4.1% |
| Revenue (ttm) | 2.42B +22.8% |
| Net Income | 251.60M +12.7% |
| EPS | 7.45 +12.6% |
| Shares Out | 33.76M |
| PE Ratio | 21.89 |
| Forward PE | 20.24 |
| Dividend | 3.31 (2.00%) |
| Ex-Dividend Date | Jun 1, 2026 |
| Volume | 5,805 |
| Open | 164.70 |
| Previous Close | 163.10 |
| Day's Range | 163.50 - 165.30 |
| 52-Week Range | 146.40 - 219.90 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 210.45 (+28.56%) |
| Earnings Date | May 28, 2026 |
About Diagnostyka
Diagnostyka S.A. provides diagnostic services in Poland. The company operates as a medical laboratory, which offers services, such as ultrasound, X-ray, computed tomography, and magnetic resonance imaging. It also offers specialized research in the field of microbiology, autoimmunity, toxicology, and molecular biology, as well as human genome research, histopathological examinations, immunohistochemical tests, cytological tests, and cytogenetic tests. The company provides services to individual clients, and public and private entities. Diagnost... [Read more]
Financial Performance
In 2025, Diagnostyka's revenue was 2.42 billion, an increase of 22.77% compared to the previous year's 1.97 billion. Earnings were 251.60 million, an increase of 12.66%.
Financial StatementsNews
Diagnostyka Earnings Call Transcript: Q4 2025
Revenue grew 23.6% year-over-year, driven by strong B2B and public health program growth, with EBITDA up 15% and net profit up nearly 13%. Regulatory changes in DI and SAP implementation pose short-term challenges, but stable margins and robust cash flow support continued investment and dividends.
Diagnostyka Annual report: Q4 2025
Diagnostyka has published its Q4 2025 annual report on April 21, 2026.
Diagnostyka Slides: Q4 2025
Diagnostyka has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on April 21, 2026.
Diagnostyka Earnings Call Transcript: Q3 2025
Q3 2025 saw revenue up 26% year-on-year and recurring EBITDA over PLN 150 million, driven by higher test volumes, price increases, and diagnostic imaging. Strong cash flow and robust financials support ongoing acquisitions and innovation, with stable outlook and dividend policy.
Diagnostyka Quarterly report: Q3 2025
Diagnostyka has published its Q3 2025 quarterly earnings report on November 20, 2025.
Diagnostyka Slides: Q3 2025
Diagnostyka has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 20, 2025.
Diagnostyka Earnings Call Transcript: Q2 2025
Test volumes and profits rose year-over-year, with revenue up 22.5% and EBITDA up 24%. Strong cash flow and disciplined capital allocation support ongoing M&A and dividend policy, while wage increases and seasonality may pressure margins in H2.
Diagnostyka Quarterly report: Q2 2025
Diagnostyka has published its Q2 2025 quarterly earnings report on September 4, 2025.
Diagnostyka Slides: Q2 2025
Diagnostyka has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on September 4, 2025.
Diagnostyka Earnings Call Transcript: Q1 2025
Q1 2025 saw strong revenue and EBITDA growth, driven by higher test volumes, price increases, and diagnostic imaging expansion. Cash flow and balance sheet remain robust, with stable margins and a positive outlook for continued growth and M&A activity.
Diagnostyka Quarterly report: Q1 2025
Diagnostyka has published its Q1 2025 quarterly earnings report on May 27, 2025.
Diagnostyka Slides: Q1 2025
Diagnostyka has posted slides in relation to its Q1 2025 quarterly earnings report, which was published on May 27, 2025.